Robert J. Friedman, M.D., M.Sc. (Med.)

Posted by Allison Cotaling on

Dr. Robert J. Friedman is a practicing dermatologic oncologist in New York City and Clinical Professor at the New York University (NYU) School of Medicine, Department of Dermatology. A graduate of the Albert Einstein College of Medicine, he received the M.D. degree in May 1978. He completed a pre-doctoral fellowship in Experimental Pathology at the McMaster University, Faculty of Medicine, and an M.Sc. in Medical Sciences in 1975. He did his residency and fellowship training at the NYU School of Medicine and Bellevue Hospital and Medical Center in Anatomic Pathology, Dermatopathology and Dermatology. He was the National Institutes of Health Melanoma Fellow at NYU from 1980-1982.

He has written more than 200 peer-reviewed medical journal articles, 30 medical textbook chapters and served as Senior Editor/Co-Editor of the seminal textbook Cancer of the Skin. He has conducted global/national seminars, including the Melanoma and Clinical Oncology Symposium at the American Academy of Dermatology (AAD) annual meetings. He has served on the Melanoma/Skin Cancer Committee and Industry Liaison Committee of the AAD, and as Chairman and CEO of Dermpath, Inc. and PathSOURCE, Inc. and as Vice Chair of Inform DX.

Dr. Friedman’s expertise is in cancers of the skin, notably in clinically diagnosing and managing malignant melanoma and related lesions. At the NYU Melanoma Cooperative Group, he and colleagues originated the “ABCDs” of clinical diagnosis and self-examination of the skin as an adjunct to early detection. He is on the Scientific Advisory Board of Electro-Optical Sciences and developer of Melafind–an instrument to help diagnose melanoma, which is in Phase III clinical trials by the U.S. Food and Drug Administration. He also heads the Institute for Melanoma/Skin Cancer Research, Inc. and MDHealthPARTNERS, which funds and consults to small cancer-related companies.

His main interest is in the clinical care of patients with cancers of the skin. He has dedicated himself to helping to prevent death from melanoma through medicinal techniques, early detection and therapeutic intervention, while the search for a cure goes on.